You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 27, 2024

Litigation Details for AstraZeneca AB v. Aurobindo Pharma Ltd. (D. Del. 2014)

✉ Email this page to a colleague

« Back to Dashboard

AstraZeneca AB v. Aurobindo Pharma Ltd. (D. Del. 2014)

Docket	⤷ Sign Up	Date Filed	2014-05-23
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	Defendant	Referred To
Patents	6,395,767; 7,951,400; 8,628,799; RE44,186
Link to Docket	External link to docket

Small Molecule Drugs cited in AstraZeneca AB v. Aurobindo Pharma Ltd.

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

Details for AstraZeneca AB v. Aurobindo Pharma Ltd. (D. Del. 2014)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
2014-05-23	1		product, prior to expiration of U.S. Patent No. 7,951,400 (“the ’400 patent”). … This is an action for patent infringement arising under the patent laws of the United States, … THE ’400 PATENT 14. On May 31, 2011, the U.S. Patent and Trademark Office …copy of the ’400 patent is attached hereto as Exhibit A. The claims of the ’400 patent are valid and …includes ONGLYZA® together with the’400 patent and U.S. Patent No. RE44,186, which covers the composition	External link to document
2015-02-18	138		Infringement and Invalidity Contentions for U.S. Patent Nos. 7,951,400 and 8,628,799 by Actavis Laboratories FL… 23 May 2014 1:14-cv-00664-GMS Patent Defendant District Court, D.	External link to document
2015-04-13	155		Dismissal of Formulation Patent Claims Concerning U.S. Patent No. 7,951,400 Between AstraZeneca and Aurobindo… 23 May 2014 1:14-cv-00664-GMS Patent Defendant District Court, D.	External link to document
2015-04-13	160		CLAIMS AND COUNTERCLAIMS CONCERNINGU.S. PATENT NOS. 7,951,400 AND 8,628,799 filed by AstraZeneca AB. Signed… 23 May 2014 1:14-cv-00664-GMS Patent Defendant District Court, D.	External link to document
2015-04-13	161		Stipulation of Dismissal of Formulation Patent Claims U.S. Patent Nos. 7,951,400 AND 8,628,799 filed by AstraZeneca… 23 May 2014 1:14-cv-00664-GMS Patent Defendant District Court, D.	External link to document
2015-04-14	165		Without Prejudice of Formulation Patent Claims (U.S. Patent No. 7,951,400) Between AstraZeneca and Glenmark… 23 May 2014 1:14-cv-00664-GMS Patent Defendant District Court, D.	External link to document
2014-09-23	17		than April 18, 2014. Date of Expiration of Patent: 7,951,400 (November 30, 2028).Thirty Month Stay Deadline… Amended Supplemental information for patent cases involving an Abbreviated New Drug Application… 23 May 2014 1:14-cv-00664-GMS Patent Defendant District Court, D.	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.